Promising Clinical Trial Results From Flex Pharma

On November 6, Flex Pharma Inc. (FLKS) reported positive stage 2 clinical trial results for a new drug to treat cramps and spasticity associated with a variety of neurological disorders. Positive topline data for FLX-787 indicates that significant improvement of pain and cramping is possible for those suffering from multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and Charcot-Marie-Tooth (CMT). Flex Pharma is a clinical-stage biotechnology company.

 

Sonal detected the event and sent an alert at 7:00 am. The next trade took place at 8:04 am for $3.51. Regular market trading opened at $3.65. The stock price continued to trend up over the next few days on the positive news. Flex Pharma closed at $3.81 on November 13.

If you want to learn more about trading on clinical trial results, visit the Knowledge Center.

To see the latest weekly webinar, you can visit our Live Webinar page.

Subscribe here if you would like to start receiving these signals in real-time and start trading!